Click to Share
 
 
  1. Latest News
  2. Submit Press Release
Filter News
Show All Results
News By Country
News By Tag
Nemucore Remove


September 2015
Fr Th We Tu Mo Su Sa
4 3 2 1
August 2015
31 30 29

nemucore Press Releases

  + XML/RSS  



By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the...
By Nemucore Medical Innovations, Inc.
Worcester Polytechnic Institute grants Provost Award to Joseph Cacaccio and Eileen Wrabel for their major qualifying project work at Nemucore Medical Innovations.
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI) is a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of patients afflicted with multidrug resistant cancers.
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the publication...
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the...
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a nanomedicine company dedicated to the development and commercialization of life-saving nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the appointment of..

All Press Releases

By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the appointment of Daniel E.
By Nemucore Medical Innovations, Inc.
Election of James B Farinholt Jr. Gives Nemucore's Board a Majority of Independent Directors
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of molecularly targeted therapies to treat multidrug resistant cancers, today announced the publication of its paper "EGFR...
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the...
By Nemucore Medical Innovations, Inc.
Worcester Polytechnic Institute grants Provost Award to Joseph Cacaccio and Eileen Wrabel for their major qualifying project work at Nemucore Medical Innovations.
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI) is a privately-held biopharmaceutical company dedicated to the development and commercialization of targeted nanomedicines for the treatment of patients afflicted with multidrug resistant cancers.
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc., a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the publication...
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a privately-held biopharmaceutical company dedicated to the development and commercialization of nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the...
By Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. (NMI), a nanomedicine company dedicated to the development and commercialization of life-saving nanomedicines for the treatment of patients afflicted with multidrug resistant cancers, today announced the appointment of..
By Nemucore Medical Innovations, Inc.
NMI's Co-Founder Dr. Torchilin was named the recipient of the Journal of Drug Targeting’s Lifetime Achievement Award for 2012 for his work in multifunctional pharmaceutical nanocarriers.
By Nemucore Medical Innovations
Nemucore Medical Innovations, as part of Northeastern University’s Center of Cancer Nanotechnology Excellence (CCNE) consortium, will develop nanomedicine manufacturing processes under recent $13.5 million grant from the National Cancer Institute


Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share